GSK (GSK) begins Phase III trials of its mepolizumab antibody treatment for severe refractory...

|By:, SA News Editor

GSK (GSK) begins Phase III trials of its mepolizumab antibody treatment for severe refractory asthma after an earlier study showed that it almost halved the number of attacks in patients. Around 4% of asthma sufferers experience the severe form of the disease.